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Abstract
Objectives This UK-wide study defines the natural history of
argininosuccinic aciduria and compares long-term neurologi-
cal outcomes in patients presenting clinically or treated pro-
spectively from birth with ammonia-lowering drugs.
Methods Retrospective analysis of medical records prior to
March 2013, then prospective analysis until December 2015.
Blinded review of brain MRIs. ASL genotyping.
Results Fifty-six patients were defined as early-onset (n= 23) if
symptomatic < 28 days of age, late-onset (n= 23) if symptomatic
later, or selectively screened perinatally due to a familial proband
(n = 10). The median follow-up was 12.4 years (range 0–53).
Long-term outcomes in all groups showed a similar neurological
phenotype including developmental delay (48/52), epilepsy (24/
52), ataxia (9/52), myopathy-like symptoms (6/52) and abnormal
neuroimaging (12/21). Neuroimaging findings included
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parenchymal infarcts (4/21), focal white matter hyperintensity
(4/21), cortical or cerebral atrophy (4/21), nodular heterotopia
(2/21) and reduced creatine levels in whitematter (4/4). 4/21 adult
patients went to mainstream school without the need of additional
educational support and 1/21 lives independently. Early-onset pa-
tients had more severe involvement of visceral organs including
liver, kidney and gut.All early-onset and half of late-onset patients
presented with hyperammonaemia. Screened patients had normal
ammonia at birth and received treatment preventing severe
hyperammonaemia. ASL was sequenced (n= 19) and 20 muta-
tions were found. Plasma argininosuccinate was higher in early-
onset compared to late-onset patients.
Conclusions Our study further defines the natural history of
argininosuccinic aciduria and genotype–phenotype correla-
tions. The neurological phenotype does not correlate with the
severity of hyperammonaemia and plasma argininosuccinic ac-
id levels. The disturbance in nitric oxide synthesis may be a
contributor to the neurological disease. Clinical trials providing
nitric oxide to the brain merit consideration.
Abbreviations
ALT Alanine aminotransferase
ASA Argininosuccinic aciduria
ASL Argininosuccinate lyase
CSF Cerebro spinal fluid
NO Nitric oxide
NOS Nitric oxide synthase
UCD Urea cycle defects
Introduction
In the central nervous system, nitric oxide (NO) is involved in
crucial processes including neurotransmission (Garthwaite
2008), neuronal differentiation (Peunova and Enikolopov
1995) and migration (Nott et al. 2013). Argininosuccinate
lyase (ASL) cleaves argininosuccinate into arginine and fuma-
rate as part of the NO-citrulline cycle that regulates NO pro-
duction in multiple tissues (e-Figure 1) (Nagamani et al.
2012a). ASL deficiency causes argininosuccinic aciduria
(ASA; OMIM 207900), the only inherited condition proven
to cause systemic NO deficiency (Erez et al. 2011). ASL is
also required for the liver-based urea cycle, which detoxifies
ammonia produced by amino acid catabolism. ASA is the
second most common urea cycle defect (UCD) with an inci-
dence of 1:70,000 live-births (Nagamani et al. 2012a) and
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presents clinically either as an early neonatal-onset (<28 days
of age) hyperammonaemic coma, or a later-onset
hyperammonaemic crisis (Nagamani et al. 2012a). A chronic
phenotype with neurocognitive, gastrointestinal and liver
symptoms without severe hyperammonaemia is also
recognised (Nagamani et al. 2012a). Conventional treatment
aims to decrease ammonia by use of a protein-restricted diet
and ammonia scavenger drugs (sodium benzoate and
phenylbutyrate) and to correct arginine deficiency by L-
arginine supplementation (Haberle et al. 2012).
The phenotype in ASA differs from other UCD by the
higher incidence of neurocognitive symptoms, liver fibro-
sis, renal impairment and systemic hypertension (Nagamani
et al. 2012a; Kolker et al. 2015). These symptoms are ob-
served in patients with early- or late-onset forms and in those
without documented episodes of hyperammonaemia (Marble
et al. 2008). Among UCD, ASA patients have the lowest
frequency of hyperammonaemic crises (23%) but the second
highest frequency of cognitive impairment (65–74%) after
arginase deficiency (Ruegger et al. 2014; Waisbren et al.
2016). This paradox raises questions about the role of
hyperammonaemia in causing the neurological problems.
Newborns screened and treated prospectively from birth
have been reported to have a better neurological outcome
(Widhalm et al. 1992; Ficicioglu et al. 2009; Mercimek-
Mahmutoglu et al. 2010). As conventional treatment de-
creases ammonia levels, it was suggested that neurological
comp l i c a t i on s we r e c a u s e d b y un r e c o g n i s e d
hyperammonaemic episodes (Widhalm et al. 1992).
However, newborn screening programmes can capture a
wide phenotypic spectrum, including patients who would
remain asymptomatic without treatment. Some of these
screened patients had high residual ASL activity
(Ficicioglu et al. 2009), suggesting that the prospectively
treated cohort might have had an increased number of mild
cases, introducing a bias into the comparison.
We describe a United Kingom (UK) wide cohort of
ASA patients expanding the disease natural history,
reporting long-term neurological outcomes with a focus
on neuroimaging and genotype–phenotype correlations.
The outcomes in patients treated prospectively (10/56)
were compared with those who presented with symptoms
before diagnosis (46/56).
Material and methods
Patients
Anonymised data were collected prospectively from
March 2013 and retrospectively before, from five tertiary
metabolic centres in the UK: Birmingham Children’s
Hospital, Birmingham; Guy’s and St Thomas’ Hospital,
London; Great Ormond Street Hospital for Children,
London; the National Hospital for Neurology and
Neurosurgery, London; the Royal Manchester Children
Hospital, Manchester. Molecular analysis of patients was
approved by the National Research Ethics Service
Committee London-Bloomsbury (13/LO/0168). Patients in-
cluded had plasma argininosuccinic acid levels > 5 μmol/L,
and/or pathogenic mutations in ASL. Patients were considered
lost to follow-up if no clinical assessment was performed dur-
ing the last 3 years at the relevant metabolic centre. The data-
base was closed on 31st December 2015.
Neurological outcome was assessed with physical neuro-
logical examination regarding developmental impairment, ep-
ilepsy, ataxia, myopathy-like symptoms and brain MRI fea-
tures and was performed as follows: if neuropsychological
assessment was unavailable, cognitive impairment was deter-
mined by clinical judgement of the metabolic specialist or
neuropaediatrician or by the need for additional support in
school or subsequently at the workplace. Epilepsy was de-
fined as the occurrence of two or more seizures without ac-
companying hyperammonaemia. MR spectroscopy was per-
formed as described previously (Davison et al. 2011).
Indication for neuroimaging was an unexplained and/or se-
vere neurological disease. Brain MRIs were analysed by
two neuroradiologists blinded to the report of each other.
Magnetic resonance spectroscopy (MRS) studies were
performed concurrently with clinically indicated MRI
scans at 1.5 T. Comparison was made with MRS metab-
olite data from a standard cohort of children with normal
appearing MRI as described previously. Liver involve-
ment was considered using the following parameters: he-
patomegaly, increased levels of transaminases (alanine amino-
transferase ALT > 50 IU/L). Nephromegaly was defined as
renal length on ultrasound imaging above the 95th centile
for the age and sex. Biochemical data were assessed using
the mean of at least the last ten results available during com-
pensated metabolic state. Plasma ammonia levels were con-
sidered elevated if >100 μmol/L before 28 days of life or
>45 μmol/L subsequently. Hypokalaemia was defined as a
plasma potassium level lower than 3.5 mmol/L and judged
as Btransient^ if observed in a single sample, or Bpersistent^
if measured in ≥ 2 samples separated by ≥ 1 month. Plasma
arginine and argininosuccinic acid reflect the last ten measure-
ments performed during follow-up in a compensated metabol-
ic state on the patient’s standard treatment. For analysis, pa-
tients were divided into three groups: (i) early-onset form
(hyperammonaemic symptoms started on/before 28 days of
life), (ii) late-onset form (presentation after 28 days of life),
(iii) perinatally screened patients diagnosed after a family pro-
band and treated prospectively from birth. For the last group,
the status (early- or late-onset) of the familial proband was
investigated but missing data prevented inclusion of these
index cases into the study.
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ASL sequencing
The 16 coding exons of ASL (NM_001024943.1; Ensembl
ENST00000395332) and the intron-exon boundaries were
PCR-amplified. Sequencing performed with the Big Dye
Terminator Cycle Sequencing System version 1.1 (Applied
Biosystems/ThermoFisher Scientific) was run on an ABI
PRISM 3730 DNA Analyzer (Applied Biosystems/
ThermoFisher Scientific) (e-Methods).
Statistical analysis
Statistical analyses used Fisher’s exact test for investigating
the association between categorical data and the patient
groups (www.vassarstats.net). Continuous variables between
groups were compared using the Student’s t test or one-way
ANOVAwith Bonferroni correction for pairwise comparison
(p values detailed in e-Table 1) (GraphPad Prism 5.0, San
Diego, CA, USA). p values ≤ 0.05 were considered statistical-
ly significant. Kaplan-Meier survival curves were compared
with the log-rank test. Patients 10, 18 and 52, who died during
the first month of life, and patient 53, for whom very limited
clinical information was available, were excluded from long-
term analysis. For patients lost during follow-up (n = 6), the
assessments at their last follow-up visits were used for
analysis.
Results
Patients
Fifty-six patients were classified as early-onset (n = 23/56),
late-onset (n = 23/56) or screened patients (n = 10/56).
Ethnic origins were White British (n = 24; 44%), Pakistani
(n = 16; 29%), Chinese (n = 6; 11%), Indian (n = 5; 9%),
Bangladeshi (n = 3; 5%), other White European (n = 1; 2%)
and missing data (n = 1; 2%) (e-Table 3). Screened patients,
diagnosed either antenatally or neonatally, had an affected
familial proband with early-onset (n = 5), late-onset (n = 3)
or unknown (n = 2) phenotype (e-Table 3). One pair of sib-
lings with early-onset form (patients 15 and 16) was included
in the study. Mean follow-up was not significantly different
between the early-onset (EO) or late-onset (LO) groups com-
pared to the screened group (SCR) (p = 0.19 and p = 0.19
respectively) (Table 1).
Neurological phenotype
The frequency and median age of onset of the neurological
features were not significantly different between the groups
(e-Table 1).
Developmental impairment was reported in 48/52 patients
(92%) and was the most common symptom. The median age
at diagnosis was 2 years (range 0.1–6 years) (Table 1) and
when observed, developmental impairment was present be-
fore the age of 6 years in all but two patients. Only four
patients were reported with normal neurocognitive function:
three early-onset patients aged <6 months (patient 22),
23 months (patient 15) and 11 years old at last assessment
(patient 11) and one patient screened at birth (patient 47; sib-
ling to a late-onset proband, aged 8 years old at last assess-
ment) (e-Table 2). Developmental impairment was mild or
moderate affecting predominantly speech and learning ability.
Detailed information about schooling was available in 35 pa-
tients (e-Table 2). Only 6/35 patients (17%) attended main-
stream school without the need for additional educational sup-
port (patients 9, 11, 35, 36, 47 and 48 with last assessment at
25, 11, 22, 20, 8 and 16 years old respectively). Most patients
(20/35; 57%) required speech and language therapy. The neu-
ropsychological assessments identified behavioural difficul-
ties with auto- or hetero-aggression (n = 3) and learning dis-
abilities in logic and reasoning. Twenty-one adults (EO n = 3;
LO n = 17; SCR n = 1) with a median age of 22.3 years (range
18–57 years) were assessed for socioeconomic status. Five
(25%) had semi-skilled employment. Independent living was
reported in 1/12 (8%), and long-term relationships in 3/12
(25%). Patients not living independently were accommodated
in the parental (9/11; 82%) or care (2/11; 18%) homes.
Epilepsy was observed in 22/52 patients (42%) with no
significant difference of the median age of onset between
groups (Table 1). Various seizure types were reported includ-
ing generalised, partial and complex, febrile and afebrile sei-
zures. Tonic-clonic seizures were most frequent (n = 16),
followed by absence seizures (n = 5), myoclonic jerks
(n = 4), atonic seizures (n = 2) and occasionally status epilep-
ticus (n = 1) (e-Table 2). Electroencephalogram was per-
formed in three non-epileptic patients and showed an abnor-
mal pattern in two patients. 17/22 patients (77%) were treated
with an average of 1.5 antiepileptic drugs (range 0–4).
Cerebellar dysfunction was detected in early-onset and
late-onset patients (n = 3 and n = 6 respectively) with the inci-
dence of 9/52 (17%) (Table 1). Ataxia was first noticed at a
median age of 8.5 years (range 1–12) with two main age
groups at first observation, early around the age of 1 year
(n = 2) or later as teenagers (n = 7). Three patients had dyski-
nesia and tremor and one had nystagmus (e-Table 2). The mild
inconvenience caused did not require any specific medical or
surgical treatment.
Episodes of myopathy-like symptoms, reported in 7/52 pa-
tients (13%) (Table 1), included global hypotonia with a
hypomimic facial expression, and unexplained recurrent epi-
sodes of general weakness persisting several days before
spontaneous recovery. One patient (patient 28, currently aged
15.9 years) was reported with fatigable ptosis from 12 years
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old onwards. Four patients were investigated with electro-
myogram, which were always normal, including a Tensilon
test in one patient. One patient (patient 33 currently aged
26 years) presented with an electrophysiologically confirmed
episode of Guillain-Barré syndrome at 8 years old (e-Table 2).
MRI brain was performed as part of the clinical work-up in
21 patients with unexplained or severe neurological features.
The average age at the time of MRI was 12 years (range 0–
23). Twelve scans were reported as abnormal (52%) (Table 1).
Neuroimaging performed during follow-up showed small pa-
renchymal infarcts (n = 4), foci of white matter hyperintensity
on T2-weighted sequences (n = 4), nodular heterotopia (n = 2),
cortical atrophy (n = 2), cerebellar atrophy (n = 2), perirolandic
gliosis (n = 1), thalamic atrophy (n = 1), hyperintensity of cau-
date head and posterior putamen (n = 1) or isosignal between
pallidi and putamen (n = 1) (Fig. 1A and e-Table 2).
Spectroscopy of basal ganglia (n = 8; 3 early-onset, 5 late-onset)
indicated a significant decrease of N-acetylaspartate and choline
in early-onset patients compared to controls (p = 0.001 and p =
0.008, respectively). Creatine and guanidinoacetate levels in the
basal ganglia did not differ significantly between controls, early-
or late-onset groups (Fig. 1B). Spectroscopy of the white matter
(n = 4; 3 early-onset, 1 late-onset) showed a significant decrease
in creatine levels (p = 0.003) and an increase of
Fig. 1 Neuroimaging. A: Morphological brain MRI features. A, B: T2-
weighted axial images showing brain matter volume loss and mild ex
vacuo dilatation of ventricles (A) and high signal in bilateral caudate
heads and posterior putamina (arrows).C: T2-weighted axial images with
severe diffuse cerebral atrophy and ventricular dilatation. D, H:
T1-weighted coronal image with right periventricular heterotopia
(arrowheads). E, F: T2-weighted axial (E) and coronal (F) images with
evidence of right inferior frontal lobe infarct (arrow). G: T2-weighted
axial image with bilateral high signal of the peritrigonal white matter
(arrow). B 1H MR spectroscopy features in basal ganglia. Assessment
in early-onset (n = 5), late-onset (n = 3) and control (n = 63) patients
analysed using a paired t test. c 1H MR spectroscopy features in white
matter. Patients affected by argininosuccinic aciduria (n = 4) and controls
(n = 53) analysed with one way ANOVA. Graphs represent mean ± 95%
confidence interval. * p < 0.05; ** p < 0.01
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guanidinoacetate (p = 0.01) (Fig. 1C) in patients compared to
controls.
Systemic phenotype
47/56 patients (84%) were alive at the time of assessment with
no significant difference between groups, with a median follow-
up of 12.4 years (range 0–53) (Fig. 2A). Cause and age of death
were hyperammonaemic decompensation at presentation (n = 2;
patients aged day 3 and 4 of life), sepsis (n = 3; patients aged
7 days, 11 years and 20 years), extradural hematoma (n = 1;
patient aged 2 years), hepatocellular carcinoma (n = 1; patient
aged 4.5 years), acute pancreatitis (n = 1; patient aged 12 years)
and a possible arrhythmia (n = 1; patient aged 52 years).
Natural history data included the age of onset of organ
involvement or symptoms (Fig. 2B). Among neurological
symptoms, developmental delay was the first observed usual-
ly during the second or third year of life followed by epilepsy
and ataxia.
The commonest hepatic involvement was a persistent rise
in plasma alanine transaminase activity, usually accompanied
by hepatomegaly. These were significantly more frequent in
early-onset and screened patients than in late-onset patients
(p < 0.00001 and p < 0.005, respectively; e-Table 1). In
screened patients, the likelihood of hepatic abnormalities
depended on the age of onset of the disease in the familial
proband: 4/4 of screened patients with an early-onset familial
history had hepatic abnormalities compared to 1/3 with a fa-
milial late-onset phenotype (Table 1).
There was no evidence of differences between groups for
nephromegaly and poor corticomedullary differentiation assessed
by ultrasound (Table 1). Transient or persistent hypokalaemia
occurred more frequently in early-onset versus late-onset pa-
tients (p < 0.03) (Table 1). Acute metabolic decompensation,
gastroenteritis and acute diarrhoea were significantly as-
sociated with transient hypokalaemia (p < 0.005).
Trichorrhexis nodosa was observed only in late-onset pa-
tients before diagnosis and normalised with treatment
(Table 1).
Chronic profuse diarrhoea was observed in 17 patients
(33%; including early-onset n = 10, late-onset n = 3, screened
patients n = 4; Table 1). This symptom was refractory to
symptomatic and immunosuppressive treatments and caused
nutritional difficulties in several early-onset patients. Two pa-
tients had colonoscopies performed at 5 years of age and re-
peated at ages 7 and 10. Intestinal biopsies showed non-
specific mild inflammation. Chronic pancreatitis was ob-
served in one early-onset patient.
Refractory arterial hypertension was diagnosed in one
early-onset patient (patient 6) at the age of 9 years and was
sub-optimally controlled despite three antihypertensive medi-
cations. This patient died at 12 years old from acute pancrea-
titis. One late-onset patient developed atrial flutter at 60 years.
Ammonaemia, ASA levels and therapies
None of the patients in the screened group suffered severe or
prolonged hyperammonaemia. Three of these patients had an
initial ammonia level >100 μmol/L (133, 134 and 190 μmol/
L), which normalised in less than 24 hours. All early-onset
patients had hyperammonaemia at diagnosis with values sig-
nificantly higher than in the late-onset and screened groups
(p < 0.001; e-Table 1). Only 50% of the late-onset patients
were hyperammonaemic at diagnosis.
A protein-restricted diet was used in 89% of patients (100%
of the early-onset group and 80% of the late-onset group;
Table 1). All patients were treated with L-arginine with no
significant difference in the dose between groups (Table 1).
Ammonia scavenger drugs (sodium benzoate and
phenylbutyrate) were prescribed significantly more often in
the early-onset and screened groups than in the late-onset group
Fig. 2 Natural history of argininosuccinic aciduria. AKaplan-Meier sur-
vival curves for all (solid line), early-onset (dashed line), late-onset
(dashed dotted line) and screened (dotted line) patients. B Natural history
of the systemic phenotype of argininosuccinic aciduria. Mean ± standard
error of age of onset of each symptom from data of the whole cohort when
information available: developmental delay (n = 7), abnormal LFTs (n =
8), hepatomegaly (n = 18), epilepsy (n = 15), brittle hair (n = 4), ataxia
(n = 6), hypokalaemia (n = 2), high blood pressure (n = 1). Symptom fre-
quency in the total population of patients studied is presented in brackets.
ALT: plasma alanine aminotransferase activity. It was assumed that pa-
tients had normal blood pressure if hypertension was not specifically
mentioned in medical records
J Inherit Metab Dis
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(p < 0.001 and p < 0.01 respectively) and at higher doses in the
early-onset group (p = 0.03) (e-Table 1).
Plasma argininosuccinate levels were higher in early-onset
(512 ± 92 μmol/L) compared to late-onset (234 ± 64 μmol/L)
(p = 0.03) (e-Table 1).
Genotype–phenotype correlation
The genotype was available for 19 patients (Table 2). Twenty
mutations (including eight novel) were identified: 11 were
missense, five splice site, two nonsense mutations and two
deletions. A sequence alignment of ASL showed that all mis-
sense mutations affect amino acid residues that are highly
conserved across species. The deletions included a 13 base
pair deletion (c.1045_1057del, p.(Val349Cysfs*72)) and one
large deletion of approximately 2 kb which included exons 15
and 16 (c.1143+117_*1353del). Homozygous mutations ob-
served with early onset disease included c.437G>A
p.(Arg146Gln), c.749T>A p.(Met250Lys), c.1045_1057del
p.(Val349Cysfs*3), c.1143+117_*1353del and c.1153C>T
p.(Arg385Cys). Homozygous mutations observed with late-
onset disease included c.35G>A p.(Arg12Gln), c.377G>A
p.(Arg126Gln) and c.1138A>G p.(Lys380Glu). The
c.1045_1057del deletion is predicted to cause a frameshift
and introduction of a premature stop codon and the c.1143+
117_*1353del deletion is predicted to cause the loss of exons
15 and 16, and both were associated with early-onset pheno-
type. Patients homozygous for c.1143+117_*1353del were
younger brothers of a proband who was not genotyped but
presented with the early onset phenotype (Table 2).
Discussion
This study describes three groups of ASA patients (early-on-
set, late-onset and perinatally screened after a familial pro-
band) with prolonged follow-up periods and compares the
long-term outcome with regard to the time at initiation of
treatment. In contrast to previously reported patients diag-
nosed by newborn screening, this study describes screened
patients, who had a familial index case with a known
phenotype.
Neurological outcome
The most common complications of ASA were neurologi-
cal. Comparison between groups demonstrates a homoge-
neous long-term neurological outcome, with no significant
difference in frequency, severity and age of onset for all
neurological features assessed. Previously unreported neu-
roimaging findings such as focal infarcts or heterotopia
might be related to impaired NO-dependent neuronal mi-
gration or microcirculation.
The early-onset group had higher ammonia levels compared
to the late-onset group, as evidenced by differences in the am-
monia levels at diagnosis, and need for ammonia scavenger
medications and protein restriction. The screened patients also
needed more treatment to control their ammonia levels than
patients in the late-onset group because most of them (5/8)
had siblings with early-onset disease. Plasma ASA levels were
higher in early-onset compared to late-onset and screened pa-
tients. However, these differences did not affect the neurological
phenotype. These observations show that hyperammonaemia
and ASA levels are not the dominant factors causing the long-
term neurological phenotype in ASA. Previous publications
have suggested that neonatal screening and early treatment
may prevent or ameliorate the neurological disease (Widhalm
et al. 1992; Ficicioglu et al. 2009). However, an extended
Austrian cohort of neonatally screened patients, initially report-
edwith normal neurocognitive outcome at amean age of 6 years
(Widhalm et al. 1992), showed that 35% of patients (6/17; me-
dian age 13 years) had an IQ of less than 80 (Mercimek-
Mahmutoglu et al. 2010). As the neurological disease is pro-
gressive, duration of the follow-up is essential to determine the
outcome objectively. At the end of the first year, the frequency
of developmental impairment is similar to other UCD (64%)
attributable to sequelae of neonatal hyperammonaemia in early-
onset patients (Burgard et al. 2016). This frequency increases to
65–100% with time (this study; Keskinen et al. 2008; Tuchman
et al. 2008; Ah Mew et al. 2013; Ruegger et al. 2014).
Aggressive behaviour and psychiatric problems such as
psychosis and paranoid ideation were previously reported in
ASA (von Wendt et al. 1982; Odent et al. 1989; Lagas and
Ruokonen 1991; Sijens et al. 2006), although these features
were not observed in this cohort.
Systemic phenotype
Our study found a wide range of systemic complications.
All of them were more frequent in the early-onset group,
apart from trichorrhexis nodosa, although blood pressure
was not systematically investigated. Chronic diarrhoea,
not reported previously, was a major problem in many
patients with endoscopy showing mild inflammation.
This has been observed in an enterocyte-specific condi-
tional knockout mouse model, in which a loss of ASL was
associated with necrotizing enterocolitis (Premkumar
et al. 2014). A similar pattern of systemic complications
was found in the screened group, suggesting that prospec-
tive treatment has no preventative effect.
Genotype–phenotype correlation
Mutation analysis of our cohort identified genotype/
phenotype correlation for some of the mutations in agreement
with the literature.
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The frequently occurring mutation c.35G>A p.(Arg12Gln)
was associated with the late-onset phenotype in one patient as
previously suggested for homozygous and compound hetero-
zygous patients (Sampaleanu et al. 2002; Mercimek-
Mahmutoglu et al. 2010; Balmer et al. 2014). It has been
reported that the arginine 12 residue on the N-terminal loop
close to the catalytic site of ASL might influence the binding/
exit of the substrate without affecting the catalytic site
explaining the milder phenotype (Sampaleanu et al. 2002).
The novel homozygous mutation c.749T>A p.(Met250Lys)
was observed in two unrelated patients with early-onset pheno-
type. This mutation involves changes in the protein sequence
close to two other amino acid modifications also associated
with early-onset phenotype p.(Glu241Lys) and p.(Trp245fs)
(Balmer et al. 2014).
The homozygous mutation c.1153C>T p.(Arg385Cys)
has been associated previously with both early-onset (n =
4) (Kleijer et al. 2002; Keskinen et al. 2008) or late-onset
phenotypes (n = 7) (Kleijer et al. 2002; Keskinen et al.
2008). However, all patients with late-onset phenotype were
diagnosed before 20 months of life. p.(Arg385Cys) has been
reported as a founder mutation in the Finnish population
(Keskinen et al. 2008) and is associated with very low ASL
activity affecting an amino acid near the catalytic site (Hu
et al. 2015).
Pathophysiology of ASA
Various pathophysiological mechanisms have been pro-
posed to account for the long-term complications of
ASA. Argininosuccinic acid may be toxic to the brain,
either directly or via the formation of guanidino com-
pounds. Raised guanidinoacetate was reported on brain spec-
troscopy of ASA patients in the grey (3.63 ± 0.6 mmol/L) and
the white matter (3.52 ± 0.09 mmol/L) (Sijens et al. 2006; van
Spronsen et al. 2006) and may be explained by L-arginine
supplementation (Sijens et al. 2006). In our study, levels of
guanidinoacetate were similar to controls in basal ganglia but
slightly elevated in white matter (1.05 ± 0.41 mmol/L).
Patients with guanidinoacetatemethyltransferase (GAMT) de-
ficiency have much higher guanidinoacetate concentrations in
brain (3.4-3.6 mmol/L) (Stockler et al. 1994) and CSF (11–
12 μmol/L) (Stockler-Ipsiroglu et al. 2014). There is also
some evidence of raised guanidinoacetate in patients with
hyperargininaemia due to Arginase deficiency, with variable
CSF guanidinoacetate concentrations (up to 0.127 μmol/L
versus controls 0.049 μmol/L) (Deignan et al. 2010), although
the spectral peak of guanidinoacetate at 3.8 ppm was not seen
in a cohort of adult patients with hyperargininaemia (Carvalho
et al. 2014), while in a 3 year old patient a prominent peak at
3.8 ppmwas ascribed to arginine, which in vitro has resonances
at 3.75 and 3.23 ppm (Wishart et al. 2007) and may have
masked any detectable guanidinoacetate. Guanidinosuccinic
acid can be neurotoxic (D’Hooge et al. 1992) and activates N-
methyl-D-aspartate receptors (Aoyagi et al. 2001). However,
this hypothesis is not supported by the observation of the
early-onset group, which has higher levels of argininosuccinic
acid but neurological outcomes similar to the other groups.
In humans, ASL is crucial for the synthesis of L-arginine,
which becomes an essential amino acid in ASA. Arginine
deprivation, associated with altered NO-mediated immune re-
sponses, can lead to site-specific neuronal loss in animal
models of neurodegenerative diseases (Kan et al. 2015).
Arginine is a precursor for the synthesis of creatine and
agmatine (e-Figure 1). Brain spectroscopy showed creatine
deficiency (this study; Sijens et al. 2006; van Spronsen et al.
2006; Boenzi et al. 2012). However, the role of secondary
creatine deficiency in cerebral dysfunction has not been con-
vincingly demonstrated (Boenzi et al. 2012). Agmatine is in-
volved in learning (Leitch et al. 2011), neuroprotection
(Molderings and Haenisch 2012) and anticonvulsant effect
(Demehri et al. 2003). Thus, secondary agmatine deficiency
could explain some of the neurological symptoms.
Finally, several symptoms may be caused by impaired
NO synthesis. Using an AslNeo/Neo mouse model, Erez et al.
(2011) showed that defective ASL is responsible for the
loss of the catalytic function of the enzyme and affects
the structure of a multi-protein complex incorporating
NOS. This disrupts the NOS-dependent NO synthesis and
leads to systemic NO deficiency. Hypoargininaemia can lead
to uncoupling of NOS, decreased NO production and in-
creased generation of free radicals that damage tissues (e-
Figure 1) (Nagamani et al. 2012b). Reactive oxygen species
interfere with NO production and regulation of the microcir-
culation (Shu et al. 2015). In addition decreased NO levels
might affect protein S-nitrosylation (Jaffrey et al. 2001),
which in turn regulates histone methylation and gene expres-
sion (Nott and Riccio 2009). In the brain, NO plays a key-role
as a signalling molecule (Riccio 2010) involved in neurotrans-
mission (Garthwaite 2008), regulation of neuronal differenti-
ation (Peunova and Enikolopov 1995; Lameu et al. 2012) and
migration (Bredt and Snyder 1994; Nott et al. 2013). In hu-
man, NO therapy was reported to have mild neurocognitive
benefit (Nagamani et al. 2012b). In this study, NO deficiency
might account for the neuropathology underlying the neuro-
imaging findings such as local parenchymal infarcts or nodu-
lar heterotopia due to impaired microcirculation and abnormal
neuronal migration during development respectively. Besides
neurological implications, NO is involved in various physio-
logical processes such as vasodilatation (Cosby et al. 2003),
liver fibrosis (Diesen and Kuo 2011), muscle strength and
performance (De Palma et al. 2014), kidney filtration rate
(Satriano et al. 2008) and gut physiology (Vallance and
Charles 1998; Premkumar et al. 2014; Bogdan 2015).
Therefore, NO deficiency might be involved at least partially
in various symptoms highlighted in this study including
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chronic hepatitis, myopathy-like phenotype, chronic diarrhoea
and systemic hypertension.
Optimising therapeutics in ASA
This study demonstrates persisting neurological and systemic
disease not obviously related to hyperammonaemia in ASA
patients on conventional treatment. Although some organs
(liver, kidney, gut) are more frequently affected in early-
onset patients, who have higher ammonia and ASA levels,
this is strikingly not the case for the brain. Our observation
of parenchymal infarcts, nodular heterotopia and the report of
mild neurological improvement after NO therapy (Nagamani
et al. 2012b) support the role of NO deficiency in the patho-
physiology of the brain disease in ASA. Currently correction
of NO deficiency is not considered in the conventional treat-
ment of ASA. Liver transplantation (Marble et al. 2008;
Newnham et al. 2008) cures the urea cycle but would not be
expected to correct the systemic NO-arginine cycle defect.
Similarly, successful liver-targeted gene therapy in AslNeo/Neo
mouse did not correct extra-hepatic features such as defective
NO-mediated vascular relaxation (Nagamani et al. 2012b).
Future therapeutic approaches in ASA might consider
targeting the NO deficiency, which could include the use of
an enriched nitrate diet, nitrate therapy (Nagamani et al.
2012b; Erez 2013) or multiorgan-targeted gene replacement.
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